| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Galileo Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $265.94M | Series F | 8/14/2026 | $30.13M | $387.07M | $3.68 | Undisclosed Investors | ||||
 | Happy Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.16M | Series B-1 | 8/18/2026 | $26.14M | $47.78M | $1.92 | ARCH Venture Partners, OpenLoop | ||||
 | Baylor Genetics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152M | Series B | 7/1/2026 | $50M | $443.35M | $19.25 | Undisclosed Investors | ||||
 | Cresilon | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.82M | Series A-6 | 7/20/2026 | $29M | $247.14M | $0.85 | Undisclosed Investors | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||
 | Quanta Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series D | 6/24/2026 | $76.19M | $253.34M | $1.44 | Avidity Partners, Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, WS Investment Company | ||||
 | Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | ||||
 | Luna | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.17M | Series C-1 | 6/30/2026 | $59.16M | $144.21M | $0.41 | Undisclosed Investors | ||||
 | Circle Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $348.74M | Series E-1 | 8/6/2026 | $92.5M | $269.89M | $0.27 | Undisclosed Investors | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $228.41M | Series C | 7/13/2026 | $80M | $452.43M | $10.01 | Undisclosed Investors | ||||
 | Cambrian | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $351.19M | Series D | 6/29/2026 | $100M | $386.97M | $2.00 | Undisclosed Investors | ||||
 | Centivo | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $332.61M | Series C | 7/14/2026 | $107.59M | $334.91M | $1.33 | Undisclosed Investors | ||||
 | Homeward Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $100.4M | Series B-1 | 8/20/2026 | $30.4M | $398.59M | $12.85 | Undisclosed Investors | ||||
 | Truvian | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.15M | Series A-2 Prime | 7/14/2026 | $24.55M | $66.2M | $0.00 | Undisclosed Investors | ||||
 | Abcuro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $353.25M | Series D-1 | 8/18/2026 | $32.35M | $120.99M | $0.60 | New Leaf Venture Partners, Rock Springs Capital, Abrdn, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, New Enterprise Associates, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, ShangBay Capital | ||||
 | cAMPfield Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180M | Series A | 6/18/2026 | $177.98M | $297.85M | $5.22 | Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital | ||||
 | Kallyope | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $573.45M | Series E | 8/31/2026 | $93.99M | $290.16M | $0.79 | Undisclosed Investors | ||||
 | LifeMine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $522.71M | Series E | 8/6/2026 | $150.54M | $469.78M | $0.78 | Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners | ||||
 | Barricaid | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.99M | Series V | 7/14/2026 | $25M | $115.7M | $0.66 | Undisclosed Investors | ||||
 | Pearl Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.27M | Series C | 7/8/2026 | $50M | $284.96M | $0.67 | Andreessen Horowitz, Viking Global Investors, AlleyCorp, Ulysses Capital, Gaingels, Alumni Ventures | ||||
 | Cooler Heads | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $23.97M | Series A-3 | 7/10/2026 | $3.27M | $34.04M | $1.15 | Undisclosed Investors | ||||
 | Hexagon Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $258.62M | Series C | 7/10/2026 | $50M | $128.86M | $0.57 | Undisclosed Investors | ||||
 | Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | ||||